• 第三軍醫(yī)大學(xué)西南醫(yī)院普外Ⅰ科（重慶400038）;

目的  探討胃癌生物治療的現(xiàn)狀與研究進(jìn)展。
方法  采用文獻(xiàn)回顧的方法對(duì)胃癌生物治療現(xiàn)狀及其研究進(jìn)展進(jìn)行綜述。
結(jié)果  胃癌生物治療的研究?jī)?nèi)容及主要方法包括： 免疫調(diào)節(jié)劑治療，單克隆抗體及其交聯(lián)物導(dǎo)向治療，細(xì)胞因子治療，過(guò)繼免疫治療，基因治療等。
結(jié)論  生物治療作為手術(shù)和放/化療的有益補(bǔ)充，在胃癌綜合治療中發(fā)揮著重要的輔助作用。

引用本文： 朱金明,余佩武. 胃癌生物治療現(xiàn)狀與展望. 中國(guó)普外基礎(chǔ)與臨床雜志, 2004, 11(2): 127-129. doi: 復(fù)制

1. Jung YD, Mansfield PF, Akagi M, et al. Effects of combination antivascular endothelial growth factor receptor and antiepidermal growth factor receptor therapies on the growth of gastric cancer in a nude mouse model [J]. Eur J Cancer, 2002; 38(8)∶1133.
2. Matsumoto K, Konno H, Tanaka T, et al. Combination therapy with vascular endothelial growth factor neutralizing antibody and mitomycin C on human gastric cancer xenograft [J]. Jpn JCancer Res, 2000; 91(7)∶748.
3. Sasaki S, Ozeki I, Takekawa M, et al. Antibody treatment for cancer [J]. Nippon Geka Gakkai Zasshi, 2000; 101(9)∶607.
4. Parmiani G, Rivoltini L, Andreola G, et al. Cytokines in cancer therapy [J]. Immunol Lett, 2000; 74(1)∶41.
5. Penichet ML, Morrison SL. Antibodycytokine fusion proteins for the therapy of cancer [J]. J Immunol Methods, 2001; 248(1-2)∶91.
6. Yamaue H, Tanimura H, Mizobata S, et al. Multidisciplinary treatment for gastric cancer patients by chemoimmunotherapy [J]. Hepatogastroenterology, 1999; 46(25)∶620.
7. Yamaguchi Y, Ohta K, Shimizu K, et al. Generation of cytotoxic effector lymphocytes by MLTC using tumor cells genetically modified to secrete interleukin2 [J].Anticancer Res, 2001; 21(1B)∶669.
8. Tsunoda T, Tanimura H, Yamaue H, et al. Tumor specific CTL therapy for advanced cancer and development for cancer vaccine [J]. Hepatogastroenterology, 1999; 46（Suppl 1）∶1287.
9. Banchereau J, Steinman RM. Dendritic cells and the control of immunity [J]. Nature, 1998; 392(6673)∶245.
10. Nair SK, Morse M, Boczkowski D, et al. Induction of tumorspecific cytotoxic T lymphocytes in cancer patients by autologous tumor RNAtransfected dendritic cells [J].Ann Surg, 2002; 235(4)∶540.
11. 孫黎飛, 劉江, 曹雪濤, 等. IL2基因修飾增強(qiáng)樹(shù)突狀細(xì)胞抗原提呈功能及其機(jī)制 [J]. 中華血液學(xué)雜志, 2002; 23(5)∶247.
12. 章衛(wèi)平, 何龍, 曹雪濤. 淋巴細(xì)胞趨化因子基因修飾增強(qiáng)腫瘤抗原多肽致敏的樹(shù)突狀細(xì)胞的抗腫瘤免疫效果 [J]. 中華醫(yī)學(xué)雜志, 1999; 79(3)∶170.
13. Gong J, Avigan D, Chen D, et al. Activation of antitumor cytotoxic T lymphocytes by fusions of human dendritic cells and breast carcinoma cells [J]. Proc Natl Acad Sci USA, 2000; 97(6)∶2715.
14. Pulendran B, Lingappa J, Kennedy MK, et al. Developmental pathways of dendritic cells in vivo: distinct function, phenotype, and localization of dendritic cell subsets in FLT3 ligand-treated mice [J]. J Immunol, 1997; 159(5)∶2222.
15. Yi Q, Desikan R, Barlogie B, et al. Optimizing dendritic cellbased immunotherapy in multiple myeloma [J]. Br J Haematol, 2002; 117(2)∶297.
16. 余文林, 黃宗海. 自殺基因治療胃腸道腫瘤的研究進(jìn)展 [J]. 中國(guó)普外基礎(chǔ)與臨床雜志, 1999; 6(3)∶781.
17. Naka K, Yokozaki H, Yasui W, et al. Effect of antisense human telomerase RNA transfection on the growth of human gastric cancer cell lines [J]. Biochem Biophys Res Commun, 1999; 255(3)∶753.
18. Steele RJ, Lane DP. Gene therapy for gastric cancer: problems and prospects [J]. Surg Oncol, 2000; 9(1)∶13.
19. Vile RG, Russell SJ, Lemoine NR. Cancer gene therapy: hard lessons and new courses [J]. Gene Ther, 2000; 7(1)∶2.
20. 錢(qián)其軍, 車(chē)小燕, 岑信棠, 等. 基因病毒載體的研制及其抗腫瘤作用的初步研究 [J]. 中華醫(yī)學(xué)雜志, 2002; 82(8)∶557.
21. Smith ER, Chiocca EA. Oncolytic viruses as novel anticancer agents: turning one scourge against another [J]. Expert Opin Investig Drugs, 2000; 9(2)∶311.
22. Hermiston T. Gene delivery from replicationselective viruses: arming guided missiles in the war against cancer [J]. J Clin Invest, 2000; 105(9)∶1169.
23. Kim R, Minami K, Nishimoto N, et al. Enhancement of antitumor effect by intratumoral administration of bax gene in combination with anticancer drugs in gastric cancer [J]. Int J Oncol, 2001; 18(2)∶363.
24. 劉君, 李寧, 宋少柏. 胃癌的分子生物學(xué)研究進(jìn)展 [J]. 中國(guó)普外基礎(chǔ)與臨床雜志, 2000; 7(3)∶791.
25. Mologni L, Marchesi E, Nielsen PE, et al. Inhibition of promyelocytic leukemia (PML)/retinoic acid receptoralpha and PML expression in acute promyelocytic leukemia cells by antiPML peptide nucleic acid [J]. Cancer Res, 2001; 61(14)∶5468.
  1. 1. Jung YD, Mansfield PF, Akagi M, et al. Effects of combination antivascular endothelial growth factor receptor and antiepidermal growth factor receptor therapies on the growth of gastric cancer in a nude mouse model [J]. Eur J Cancer, 2002; 38(8)∶1133.
  2. 2. Matsumoto K, Konno H, Tanaka T, et al. Combination therapy with vascular endothelial growth factor neutralizing antibody and mitomycin C on human gastric cancer xenograft [J]. Jpn JCancer Res, 2000; 91(7)∶748.
  3. 3. Sasaki S, Ozeki I, Takekawa M, et al. Antibody treatment for cancer [J]. Nippon Geka Gakkai Zasshi, 2000; 101(9)∶607.
  4. 4. Parmiani G, Rivoltini L, Andreola G, et al. Cytokines in cancer therapy [J]. Immunol Lett, 2000; 74(1)∶41.
  5. 5. Penichet ML, Morrison SL. Antibodycytokine fusion proteins for the therapy of cancer [J]. J Immunol Methods, 2001; 248(1-2)∶91.
  6. 6. Yamaue H, Tanimura H, Mizobata S, et al. Multidisciplinary treatment for gastric cancer patients by chemoimmunotherapy [J]. Hepatogastroenterology, 1999; 46(25)∶620.
  7. 7. Yamaguchi Y, Ohta K, Shimizu K, et al. Generation of cytotoxic effector lymphocytes by MLTC using tumor cells genetically modified to secrete interleukin2 [J].Anticancer Res, 2001; 21(1B)∶669.
  8. 8. Tsunoda T, Tanimura H, Yamaue H, et al. Tumor specific CTL therapy for advanced cancer and development for cancer vaccine [J]. Hepatogastroenterology, 1999; 46（Suppl 1）∶1287.
  9. 9. Banchereau J, Steinman RM. Dendritic cells and the control of immunity [J]. Nature, 1998; 392(6673)∶245.
  10. 10. Nair SK, Morse M, Boczkowski D, et al. Induction of tumorspecific cytotoxic T lymphocytes in cancer patients by autologous tumor RNAtransfected dendritic cells [J].Ann Surg, 2002; 235(4)∶540.
  11. 11. 孫黎飛, 劉江, 曹雪濤, 等. IL2基因修飾增強(qiáng)樹(shù)突狀細(xì)胞抗原提呈功能及其機(jī)制 [J]. 中華血液學(xué)雜志, 2002; 23(5)∶247.
  12. 12. 章衛(wèi)平, 何龍, 曹雪濤. 淋巴細(xì)胞趨化因子基因修飾增強(qiáng)腫瘤抗原多肽致敏的樹(shù)突狀細(xì)胞的抗腫瘤免疫效果 [J]. 中華醫(yī)學(xué)雜志, 1999; 79(3)∶170.
  13. 13. Gong J, Avigan D, Chen D, et al. Activation of antitumor cytotoxic T lymphocytes by fusions of human dendritic cells and breast carcinoma cells [J]. Proc Natl Acad Sci USA, 2000; 97(6)∶2715.
  14. 14. Pulendran B, Lingappa J, Kennedy MK, et al. Developmental pathways of dendritic cells in vivo: distinct function, phenotype, and localization of dendritic cell subsets in FLT3 ligand-treated mice [J]. J Immunol, 1997; 159(5)∶2222.
  15. 15. Yi Q, Desikan R, Barlogie B, et al. Optimizing dendritic cellbased immunotherapy in multiple myeloma [J]. Br J Haematol, 2002; 117(2)∶297.
  16. 16. 余文林, 黃宗海. 自殺基因治療胃腸道腫瘤的研究進(jìn)展 [J]. 中國(guó)普外基礎(chǔ)與臨床雜志, 1999; 6(3)∶781.
  17. 17. Naka K, Yokozaki H, Yasui W, et al. Effect of antisense human telomerase RNA transfection on the growth of human gastric cancer cell lines [J]. Biochem Biophys Res Commun, 1999; 255(3)∶753.
  18. 18. Steele RJ, Lane DP. Gene therapy for gastric cancer: problems and prospects [J]. Surg Oncol, 2000; 9(1)∶13.
  19. 19. Vile RG, Russell SJ, Lemoine NR. Cancer gene therapy: hard lessons and new courses [J]. Gene Ther, 2000; 7(1)∶2.
  20. 20. 錢(qián)其軍, 車(chē)小燕, 岑信棠, 等. 基因病毒載體的研制及其抗腫瘤作用的初步研究 [J]. 中華醫(yī)學(xué)雜志, 2002; 82(8)∶557.
  21. 21. Smith ER, Chiocca EA. Oncolytic viruses as novel anticancer agents: turning one scourge against another [J]. Expert Opin Investig Drugs, 2000; 9(2)∶311.
  22. 22. Hermiston T. Gene delivery from replicationselective viruses: arming guided missiles in the war against cancer [J]. J Clin Invest, 2000; 105(9)∶1169.
  23. 23. Kim R, Minami K, Nishimoto N, et al. Enhancement of antitumor effect by intratumoral administration of bax gene in combination with anticancer drugs in gastric cancer [J]. Int J Oncol, 2001; 18(2)∶363.
  24. 24. 劉君, 李寧, 宋少柏. 胃癌的分子生物學(xué)研究進(jìn)展 [J]. 中國(guó)普外基礎(chǔ)與臨床雜志, 2000; 7(3)∶791.
  25. 25. Mologni L, Marchesi E, Nielsen PE, et al. Inhibition of promyelocytic leukemia (PML)/retinoic acid receptoralpha and PML expression in acute promyelocytic leukemia cells by antiPML peptide nucleic acid [J]. Cancer Res, 2001; 61(14)∶5468.